MedPath

Novel Bioactive Sleeve on Pain and PROMs

Not Applicable
Recruiting
Conditions
Meniscus Tear
Interventions
Device: Reparel Sleeve
Device: Placebo Sleeve
Registration Number
NCT06041321
Lead Sponsor
Northwell Health
Brief Summary

A novel bioactive sleeve will be compared to a placebo sleeve with a similar look and feel to assess pain outcomes, patient reported outcome measures, and effectiveness of healing based on range of motion.

Detailed Description

This is a blinded randomized prospective study comparing two postoperative leg sleeves. The novel bioactive sleeve (Reparel Leg Sleeve) will be compared to a regular black sleeve with a similar feel/compression. The main hypothesis for this study is that postoperative use of a novel bioactive sleeve after partial arthroscopic meniscectomy/meniscus repair will decrease pain and improve patient reported outcome scores faster and more reliably than the control non-bioactive sleeve. In order to test this hypothesis, approximately 100 patients scheduled for meniscectomy/meniscus repair will be randomized to one of the two arms in order to minimize bias. The following variables will be assessed: patient reported outcomes (VAS, KOOS JR, VR12, and KSS Satisfaction), physical therapy time, motor testing. Each patient will fill out a series of PROMs preoperatively, and post operatively at the 1-week, 2-week, 6-week, 3-month, 6-month, 1 year, and 2-year mark.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, over the age of 18, undergoing a meniscectomy or meniscus repair
  • In good general health as evidenced by medical history
  • Under 45th percentile BMI
  • Willing to adhere to the study intervention regimenregimen.
  • Kellgren-Lawrence grade 2 or less
Exclusion Criteria
  • Febrile illness within 3 months
  • BMI over 40
  • Treatment with another investigational drug or other intervention within 6 months
  • Kellgren-Lawrence grade 3 or more or 4
  • History of autoimmune disease, circulatory disease, or vascular disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Reparel SleeveReparel SleeveDevice size(s): Small, medium, large, x-large Device model(s): Reparel Leg Sleeve (full length) Description of each component: Fabric garment constructed of 41% Polyester embedded with a proprietary non-metal semiconductive nano-sized material, 13% Polyester, 27% Nylon, and 19% Lycra-Spandex. The top cuff of the garment has silicone grips to keep the garment from sliding down. 501k exempt: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=FQL Company Name: Challenger Health, LLC (dba Reparel) FDA Registration Number: 3012651665 Device Listing Number: D269770 Product Classification: Class I Medical Device, 510(k) exempt Product Code: FQL, Stocking/Medical Support
Placebo SleevePlacebo SleeveDevice size(s): Small, medium, large, x-large Device model(s): Generic Black Leg Sleeve Supplier: Jupin Group Co., Ltd. Description of each component: Fabric garment constructed of 80% polyester and 20% lycra
Primary Outcome Measures
NameTimeMethod
Visual Analogue Scale (VAS) pain score2 years

Assessing the effectiveness of a bioactive sleeve against a non-bioactive sleeve with regard to pain. The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

Secondary Outcome Measures
NameTimeMethod
Range of Motion2 years

Assessing the effectiveness of a bioactive sleeve against a non-bioactive sleeve with regard to range of motion testing. Range of motion is calculated by degrees of flexion and extension of the knee.

Trial Locations

Locations (1)

Orlin and Cohen Orthopedics

馃嚭馃嚫

Woodbury, New York, United States

漏 Copyright 2025. All Rights Reserved by MedPath